ONCOVIR Trademark

Trademark Overview

On Friday, February 14, 2003, a trademark application was filed for ONCOVIR with the United States Patent and Trademark Office. The USPTO has given the ONCOVIR trademark a serial number of 78215231. The federal status of this trademark filing is REGISTERED AND RENEWED as of Tuesday, February 2, 2016. This trademark is owned by Ribopharm, Inc.. The ONCOVIR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for treatment of viral and oncological disease
oncovir

General Information

Serial Number78215231
Word MarkONCOVIR
Filing DateFriday, February 14, 2003
Status800 - REGISTERED AND RENEWED
Status DateTuesday, February 2, 2016
Registration Number3154691
Registration DateTuesday, October 10, 2006
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 12, 2004

Trademark Statements

Goods and ServicesPharmaceuticals for treatment of viral and oncological disease

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 7, 2003
Primary Code005
First Use Anywhere DateFriday, May 26, 2006
First Use In Commerce DateWednesday, May 31, 2006

Trademark Owner History

Party NameONCOVIR, INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressWASHINGTON, DC 20008
Party NameONCOVIR, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWASHINGTON, DC 20008
Party NameONCOVIR, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressWASHINGTON, DC 20008
Party NameRibopharm, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWashington, DC 200083450

Trademark Events

Event DateEvent Description
Tuesday, February 2, 2016NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - MAILED
Tuesday, February 2, 2016REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Tuesday, February 2, 2016REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Tuesday, February 2, 2016CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, November 17, 2015TEAS SECTION 8 & 9 RECEIVED
Thursday, February 16, 2012NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - MAILED
Thursday, February 16, 2012REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Thursday, February 16, 2012CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Friday, January 6, 2012TEAS SECTION 8 & 15 RECEIVED
Tuesday, October 10, 2006REGISTERED-PRINCIPAL REGISTER
Saturday, August 26, 2006LAW OFFICE REGISTRATION REVIEW COMPLETED
Friday, August 18, 2006ASSIGNED TO LIE
Tuesday, August 15, 2006ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, August 2, 2006STATEMENT OF USE PROCESSING COMPLETE
Friday, June 30, 2006USE AMENDMENT FILED
Friday, June 30, 2006PAPER RECEIVED
Wednesday, January 25, 2006EXTENSION 2 GRANTED
Thursday, December 29, 2005EXTENSION 2 FILED
Thursday, December 29, 2005PAPER RECEIVED
Tuesday, July 12, 2005EXTENSION 1 GRANTED
Wednesday, June 29, 2005EXTENSION 1 FILED
Wednesday, June 29, 2005PAPER RECEIVED
Tuesday, January 4, 2005NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 12, 2004PUBLISHED FOR OPPOSITION
Wednesday, September 22, 2004NOTICE OF PUBLICATION
Friday, August 13, 2004LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, August 2, 2004ASSIGNED TO LIE
Monday, July 26, 2004APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 9, 2004PETITION TO REVIVE-GRANTED
Tuesday, July 6, 2004TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, March 8, 2004PETITION TO REVIVE-RECEIVED
Thursday, April 1, 2004ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, March 8, 2004PAPER RECEIVED
Friday, July 25, 2003NON-FINAL ACTION E-MAILED
Wednesday, July 23, 2003ASSIGNED TO EXAMINER

Related Keywords

oncovir disease oncological viral treatment pharmaceuticals